In the context of the very high penetrance of KRAS mutations in pancreatic cancers, targeting metabolic enzymes was effective in treating KRAS-mutant tumours in pre-clinical lung cancer models [12]. This evidence concerns the gene KRAS and familial pancreatic carcinoma.